Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 352

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 19
Chunk 352
---
 ADS. The Company also issued to investors in the offering unregistered warrants to pu...  

  In November 2024, the Company completed a registered direct offering to certain funds associated with Highbridge Capital Management LLC (“ Highbridge”) of 103,037 ADSs and 308,749 pre-funded wa...  

  Share purchase agreement  

In September 2021, the Company entered into an ATM sales agreement with H. C. Wainwright & Co., LLC (“ HCW”), pursuant to which the Company is entitled, at its sole discretion, to offer and sell through HCW, acting as sales agent, ADSs having an aggregate offering price of up to $25.0million throughout the period during which the ATM facility remains in effect. The Company agreed to pay HCW a commission of3.0% of the gross proceeds from the sale of ADSs under the facility. During 2024, no ADSs were sold under the facility. From the effective date of the agreement through the issuance date of this report,194,656ADSs have been sold under the facility for total gross proceeds of approximately $6.0million and total fees of approximately $0.2million.

  Share-based payments  

  Share Incentive plan – general  

In 2003, the Company adopted the 2003 Share Incentive Plan (the “ Plan”). The Plan provides for the granting of stock options and ordinary shares to the Company’s employees, directors, consultants and other service providers. Options are issued at the determination of the Board of Directors in accordance with applicable law. The options are generally exercisable for a ten-year period and the grants generally vest over a four-year period. In 2013, the Company’s Board of Directors approved amendments to the Plan to take into account changes in laws and regulations that had occurred since its adoption and to extend the term of the plan until November 2023. In 2016, the Board of Directors approved amendments to the Plan to allow for the grant of restricted stock units (“ RSUs”) and performance stock units (“ PSUs”). In 2022, the Board approved certain amendments to the Plan in order to conform the Plan to U. S. tax regulations for the benefit BioLineRx USA, Inc. employees. In November 2023, the Company’s Board of Directors approved extension of the Plan through May 2024, and subsequently further approved extension of the Plan through May 2044.

PSUs are RSUs that are linked to any one or more performance goals